NO974750L - Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse - Google Patents

Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse

Info

Publication number
NO974750L
NO974750L NO974750A NO974750A NO974750L NO 974750 L NO974750 L NO 974750L NO 974750 A NO974750 A NO 974750A NO 974750 A NO974750 A NO 974750A NO 974750 L NO974750 L NO 974750L
Authority
NO
Norway
Prior art keywords
compounds
treatment
motogenesis
metastasis
transfer process
Prior art date
Application number
NO974750A
Other languages
English (en)
Other versions
NO974750D0 (no
Inventor
Carlo Battistini
Patrizia Giordano
Sabrina De Rosa
Fabio Corradi
Paolo Comoglio
Alberto Bardelli
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO974750D0 publication Critical patent/NO974750D0/no
Publication of NO974750L publication Critical patent/NO974750L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår peptider og peptidomimetiske forbindelser og farmasøytiske sammensetninger som inneholder disse som nyttige farmakologiske midler i kontroll eller behandling av proliferative sykdommer slik som kanser, mot tumorvekst og/eller tumora! metastase, og psoriasis og i kontroll eller behandling av inflammatorisk, allergisk, autoimmun, viral og kardiovaskulære sykdommer. Disse nye forbindelsene har den unike egenskapen at de hemmer gjenkjenning av flere fosfotyrosininneholdende motiver i alle cellulære reseptorer og sytosole transdusere i et vidt spektrum av SH2- domener inneholdt i sytosolltransduserne og andre effektorproteiner som befinner seg langs forskjellige veier på signaloverføringsprosessen og med en særlig høy affinitet for SH2-domene av adaptortransduser Grb2, et nøkkelelement langs veien til mitogenese og motogenese, den sistnevnte aktivitet fører til invasivhet og metastase. Oppfinnelsen angår også fremgangsmåter for fremstilling av forbindelsene og metoder for behandling som benytter forbindelsene.
NO974750A 1996-02-15 1997-10-14 Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse NO974750L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603227.1A GB9603227D0 (en) 1996-02-15 1996-02-15 Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
PCT/EP1997/000595 WO1997030079A1 (en) 1996-02-15 1997-02-10 Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use

Publications (2)

Publication Number Publication Date
NO974750D0 NO974750D0 (no) 1997-10-14
NO974750L true NO974750L (no) 1997-12-10

Family

ID=10788833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974750A NO974750L (no) 1996-02-15 1997-10-14 Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse

Country Status (21)

Country Link
US (1) US6245742B1 (no)
EP (1) EP0821696B1 (no)
JP (1) JPH11504658A (no)
KR (1) KR19990007783A (no)
CN (1) CN1185785A (no)
AR (1) AR005808A1 (no)
AT (1) ATE266041T1 (no)
AU (1) AU1768297A (no)
BR (1) BR9702084A (no)
CA (1) CA2218378A1 (no)
DE (1) DE69728938D1 (no)
EA (1) EA199700318A1 (no)
GB (1) GB9603227D0 (no)
HU (1) HUP9900661A3 (no)
IL (1) IL121853A0 (no)
MX (1) MX9707771A (no)
NO (1) NO974750L (no)
NZ (1) NZ328895A (no)
PL (1) PL322779A1 (no)
WO (1) WO1997030079A1 (no)
ZA (1) ZA971171B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055463A1 (en) * 1998-12-24 2002-05-09 Christiane Garbay Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same
FR2787793B1 (fr) * 1998-12-24 2001-03-23 Inst Nat Sante Rech Med Composes pseudopeptidiques dotes d'une activite inhibitrice a l'egard des voies activees par les proteines a activite tyrosine kinase et les compositions pharmaceutiques les contenant
FR2793796A1 (fr) * 1999-04-14 2000-11-24 Hoechst Marion Roussel Inc Nouveaux derives d'imidazoles, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2796381A1 (fr) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Derives bicycliques de thioazepine ou de caprolactame, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
US7736911B2 (en) * 2004-04-15 2010-06-15 Albert Einstein College Of Medicine Of Yeshiva University Activity-based probes for protein tyrosine phosphatases
EP2140267B1 (en) 2007-02-26 2017-11-15 StemCell Technologies Inc. Method of reducing curvature in a meniscus of liquid medium
US8703072B2 (en) 2008-09-12 2014-04-22 Oliver Egeler Cell culture vessels for meniscus reduction with aqueous solutions
CN103387602B (zh) * 2012-05-09 2018-07-06 中国科学院上海药物研究所 一种新型开链四肽类似物及其制备方法和用途
EP2943409B1 (en) 2013-01-10 2020-12-23 Stemcell Technologies Inc. Meniscus reducing member
US10537891B2 (en) 2013-01-10 2020-01-21 Stemcell Technologies Inc. Meniscus reducing member

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801149A (en) * 1991-06-19 1998-09-01 Joslin D-Abetes Center, Inc. Inhibition of signal transduction molecules
US5739278A (en) * 1993-05-10 1998-04-14 University Of Washington Compositions for protein tyrosine phosphatases
WO1995001376A1 (en) 1993-06-30 1995-01-12 Pharmacia S.P.A. Peptide inhibitors of mitogenesis and motogenesis
AU4972096A (en) * 1995-02-01 1996-08-21 Affymax Technologies N.V. Peptides and compounds that bind to sh2 domains
GB9516842D0 (en) * 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) * 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives

Also Published As

Publication number Publication date
NZ328895A (en) 1999-03-29
CA2218378A1 (en) 1997-08-21
HUP9900661A2 (hu) 1999-08-30
PL322779A1 (en) 1998-02-16
IL121853A0 (en) 1998-02-22
KR19990007783A (ko) 1999-01-25
MX9707771A (es) 1997-12-31
BR9702084A (pt) 1999-07-20
EA199700318A1 (ru) 1998-04-30
ZA971171B (en) 1997-09-03
WO1997030079A1 (en) 1997-08-21
AR005808A1 (es) 1999-07-14
GB9603227D0 (en) 1996-04-17
ATE266041T1 (de) 2004-05-15
US6245742B1 (en) 2001-06-12
CN1185785A (zh) 1998-06-24
JPH11504658A (ja) 1999-04-27
DE69728938D1 (de) 2004-06-09
NO974750D0 (no) 1997-10-14
EP0821696B1 (en) 2004-05-06
HUP9900661A3 (en) 2000-03-28
AU1768297A (en) 1997-09-02
EP0821696A1 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
Birge et al. Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts
Zachary et al. Bombesin, vasopressin, and endothelin rapidly stimulate tyrosine phosphorylation in intact Swiss 3T3 cells.
Heideker et al. DUBs, the regulation of cell identity and disease
Erusalimsky et al. Bombesin, diacylglycerols, and phorbol esters rapidly stimulate the phosphorylation of an Mr= 80,000 protein kinase C substrate in permeabilized 3T3 cells. Effect of guanine nucleotides.
NO974750L (no) Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse
WO1988003151A3 (en) Thrombin derived polypeptides; compositions and methods for use
Kobayashi et al. Phosphorylation of intracellular precursors of human IL-1.
WO2009136290A1 (en) Functionalized pyrrolidines and use thereof as iap inhibitors
WO2010015090A1 (en) Functionalized pyrrolidines and use thereof as iap inhibitors
CN102985439A (zh) Iap bir结构域结合化合物
Zhang et al. Inhibition of O-GlcNAc transferase (OGT) by peptidic hybrids
Babinska et al. Two regions of the human platelet F11-receptor (F11R) are critical for platelet aggregation, potentiation and adhesion
JP2005529842A (ja) 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体
Morgan et al. Dissociation of radiation-induced phosphorylation of replication protein A from the S-phase checkpoint
CN108659099A (zh) 一种用于血管紧张素转化酶活性检测的质谱探针及其应用
Yin et al. Construction of a novel bispecific antibody to enhance antitumor activity against lung cancer
Edwards et al. The cell biology of phagocytes
Pettit et al. Antineoplastic Agents. 607. Emetine Auristatins
Montagut et al. Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Baron et al. The carboxyl-terminal domain of the insulin receptor: its potential role in growth-promoting effects
WO2000002897B1 (en) Delta cleavage products and methods based thereon
Nickel et al. Constitutive expression of functionally active protease‐activated receptors 1 and 2 in human conjunctival epithelial cells
Hawkins et al. Gastrulation in the sea urchin, Strongylocentrotus purpuratus, is disrupted by the small laminin peptides YIGSR and IKVAV
Wang et al. Expression and purification of a rapidly degraded protein, TMEM8B-a, in mammalian cell line
KR20110044545A (ko) 신규한 인간 류신 지퍼 단백질 아형 및 이의 용도